Adults at least 18 years old and not more than 65 years of age with a clinical diagnosis of moderate to severe chronic plaque psoriasis with a
disease duration of at least 6 months, may qualify to participate. Individuals must have 10% or more body surface area (BSA) affected by plaque psoriasis, and have no other skin disease which may interfere with assessment of chronic plaque psoriasis.
Participants will receive investigational oral medication (active study drug) or placebo. Study medication and study-related assessments will be provided at no cost. Reimbursement for study-related expenses may be provided.
Study participation will last about 24 weeks and involve about 8 visits to the study centre, plus a follow-up phone call.
Condition or Disease:
Intervention/Treatment:Drug: Cedirogant Drug: Cedirogant Drug: Cedirogant Drug: Placebo
Ages Eligible for Study:
18 Years and 65 Years (Adult,Older Adult)
Sexes Eligible for Study:
– Participants with stable moderate to severe plaque psoriasis of at least 6 months duration and who are candidates for systemic therapy or phototherapy.
Primary non-responders to previous anti-IL-17 (e.g., secukinumab, ixekizumab, brodalumab), anti-IL-23 (e.g., guselkumab, tildrakizumab, risankizumab), or anti-IL-12/23 (e.g., ustekinumab) treatment for chronic plaque psoriasis.
Diagnosis of erythrodermic psoriasis, generalized or localized pustular psoriasis, medication-induced or medication exacerbated psoriasis, or new onset guttate psoriasis or any other skin disease which may interfere with assessment of chronic plaque psoriasis.